학술논문

Effect of HAART on salivary gland function in the Women's Interagency HIV Study (WIHS)
Document Type
Clinical report
Source
Oral Diseases. Jan, 2009, Vol. 15 Issue 1, p52, 9 p.
Subject
HIV patients
Protease inhibitors
Anti-HIV agents
Antiviral agents
Highly active antiretroviral therapy
Proteases
HIV (Viruses)
Language
English
ISSN
1354-523X
Abstract
To purchase or authenticate to the full-text of this article, please visit this link: http://dx.doi.org/10.1111/j.1601-0825.2008.01456.x Byline: M Navazesh, M Alves, R Mulligan, R Karim, WJ Mack, S Ram, H Seirawan, J Greenspan, D Greenspan, J Phelan Keywords: HIV; antiretroviral therapy; HAART; salivary gland function; salivary gland enlargement; PI based HAART Abstract: Objective: To determine the impact of highly active antiretroviral therapy (HAART) on salivary gland function in human immunodeficiency virus (HIV) positive women from the Women's Interagency HIV Study (WIHS). Design: Longitudinal cohort study. Subjects and methods: A total of 668 HIV positive women from the WIHS cohort with an initial and at least one follow-up oral sub-study visit contributed 5358 visits. Salivary gland function was assessed based on a dry mouth questionnaire, whole unstimulated and stimulated salivary flow rates, salivary gland enlargement or tenderness and lack of saliva on palpation of the major salivary glands. Main outcome measures: Changes in unstimulated and stimulated flow rates at any given visit from that of the immediate prior visit (continuous variables). The development of self-reported dry mouth (present/absent), enlargement or tenderness of salivary glands (present/absent), and absence of secretion on palpation of the salivary glands were binary outcomes (yes/no). Results: Protease Inhibitor (PI) based HAART was a significant risk factor for developing decreased unstimulated (P = 0.01) and stimulated (P = 0.0004) salivary flow rates as well as salivary gland enlargement (P = 0.006) as compared with non-PI based HAART. Conclusions: PI-based HAART therapy is a significant risk factor for developing reduced salivary flow rates and salivary gland enlargement in HIV positive patients. Article History: Received 5 February 2008; accepted 06 May 2008 Article note: M Navazesh, 925 West 34th Street, DEN 4320, USC School of Dentistry, Los Angeles, CA 90089-0641, USA. Tel: +1 213 740 1418, Fax: +1 213 821 5278, E-mail: navazesh@usc.edu